Articles related to ANTITHROMBOTIC THERAPY

Reconsideration of routine thromboprophylaxis in older adults may be warranted, as the SYMPTOMS trial found no significant difference in the prevention of symptomatic venous thromboembolism when comparing low-molecular-weight heparin with a placebo. Further research is needed to validate these results and determine the best strategies for VTE prevention in this demographic.

Evaluating the Timing of DOAC Initiation Post-Stroke: Key Findings Here are the key findings from a recent multi-country, open-label research that explores the best time to start direct oral anticoagulants (DOACs) in atrial fibrillation patients after a stroke.

Check out the updated guideline for changes prevention and treatment of VTE in a variety of cancer settings.

Because each patient reports unique challenges, there is no “one size fits all” approach to managing cancer-associated venous thrombosis (CAT). Thrombosis is a complication that HCPs are not recognizing early enough in the face of multiple options for appropriately treating and managing CAT; additionally, there is a lack of awareness of new CAT management clinical data. Although the morbidity and mortality of VTE in cancer patients remain high, unfortunately, its management is not given the same priority. And although recommendations suggest an individualized approach to managing these patients, clinical practice adoption is slow. Published guidelines and clinical trial data do not always correspond to real-world practice and prescribing practices. As a result, many existing CAT management protocols must be updated as new guidance is warranted.

Twelve-hundred (1,200) patients admitted for 48 hours or more for COVID were randomized to 2.5mg of apixaban or placebo twice daily for 30 days. The incidence of death or thromboembolism was low and similar in the two arms of this study. The study was terminated early and the authors say the results are imprecise.

In this study, more than 12,000 patients 18 years and older with hospitalization for extremity fracture were randomized to LWMH or aspirin. Rates of DVT were 1.7% and 2.5%, respectively. PE, bleeding complications, and other SAEs were similar across groups. Death occurred in 0.73% and 0.78% respectively for LWMH and aspirin.